Меню
Идёт набор NCT07409506

Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease

Наблюдательное Elderly (People Aged 65 or More) Neurocognition Alzheimer s Disease

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: " Ressources Utilisation in Dementia " (RUD) questionnaire..
Кому может быть актуально
Состояния в реестре: Elderly (People Aged 65 or More), Neurocognition, Alzheimer s Disease. Базовые параметры: от 60 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Франция
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system. Informal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease. The main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.

Вмешательства

  • Другое " Ressources Utilisation in Dementia " (RUD) questionnaire.
    Questionnaire on the use of services available to patients with dementia.

Первичные конечные точки

  • Informal care costs [Срок оценки: At inclusion or 15 days maximum after inclusion.]

Критерии участия

Критерии включения

  • Patients from Charpennes Hospital included in the MEM-AURA cohort
  • Patients aged 60 years and older at inclusion
  • Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage
  • Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion
  • Patients accompanied by a caregiver at inclusion

Критерии исключения

  • \- Patients or caregivers who have expressed their opposition to the study
  • Patients living in institutions or nursing homes
  • Patients protected by law (under legal protection, guardianship, or conservatorship)

Early termination Criteria :

\- Patients or caregivers withdrawing their consent to participate during the study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Франция · 1 центр
  • Hôpital des Charpennes — Villeurbanne

Идентификаторы

NCT: NCT07409506 · 25-5152 · 69HCL24_1258

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗